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Abstract
Summary Prior8-weektreatmentwithmenatetrenone,MK-4,
followed by 8-week risedronate prevented the shortcomings
of individual drugs and significantly increased the strength of
ovariectomized ICR mouse femur compared to the ovariec-
tomized(OVX) controls. Neither MK-4following risedronate
nor the concomitant administration may be recommended
because they brought the least beneficial effect.
Introduction The objective of this study was to determine
the best combinatory administration of risedronate at
0.25 mg/kg/day (R) with vitamin K2 at approximately
100μg MK-4/kg/day (K) to improve strength of osteoporotic
mouse bone.
Methods Thirteen-week-old ICR mice, ovariectomized at
9-week, were treated for 8 weeks with R, K, or R plus K
(R/K), and then, either the treatment was withdrawn (WO)
or switched to K or R in the case of R and K. After another
8 weeks, the mice were killed, and mechanical tests and
analyses of femur properties by peripheral quantitative
computed tomography, microfocus X-ray tube computed
tomography, and confocal laser Raman microspectroscopy
were carried out.
Results The K to R femur turned out superior in parameters
tested such as material properties, bone mineral density,
BMC, trabecular structure, and geometry of the cortex. The
increased cross-sectional moment of inertia, which occurred
after K withdrawal, was prevented by risedronate in K to R.
In addition to K to R, some properties of R to WO
diaphysis and K to WO epiphysis were significantly better
than OVX controls.
Conclusion Prior treatment with MK-4 followed by risedr-
onate significantly increased femur strength in comparison
to the OVX controls.
Keywords Bisphosphonate.Qualityofbone.Raman
spectroscopy.Risedronate.Sequentialadministration.
VitaminK2
Introduction
Bisphosphonate is one of the most effective drugs currently
available for suppressing bone resorption. Naturally, com-
bination therapies with other antiresorptive or formative
agents have been investigated: PTH [1–3], vitamin D [2, 4],
estrogen [5–7], and other agents [8]. Risedronate, a
pyridinyl (amino) bisphosphonate, significantly reduces
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Suita, Osaka, Japanthe risk of hip fracture among elderly women with
confirmed osteoporosis and if combined with estrogen or
raloxifene, produces greater gains in bone mass in
comparison to single-agent treatment [9]. Oral administra-
tion or intake from food of vitamin K2, on the other hand,
has been shown to prevent the occurrence of fractures in
Japanese women [10, 11] and was reported to prevent bone
loss partly through the improved bone formation in animal
studies [12]. It was also reported that vitamin K2 (MK-4)
inhibited bone resorption [13]. A more recent cellular study
reported that the osteoprotective action of vitamin K2 is
through steroid and xenobiotic receptor (SXR)/pregnane X
receptor (PXR)-modulated Msx2 gene transcription [14].
Such an entirely different pharmacological action of
vitamin K2 from other drugs would make it worth studying
combinatory administration with bisphosphonate. Limited
reports of trabecular bone implied that the combined
treatment is more efficacious in osteoporotic rats [15, 16],
while others have reported otherwise [17, 18]. Therefore,
the efficacy of their combinatory use was further investi-
gated in ovariectomized (OVX) ICR mice to clarify the
effect on the cortical bone and strength. We tried to separate
the effect of vitamin K2 on matrix from that on mineral and
to compare with the effect of risedronate by lowering the
experimentalvitaminK2 intake level to ~100μgM K - 4 / k g / d a y ,
which is at the dietary level.
Materials and methods
Experimental animals
The Animal Care Committee of Kanagawa Dental College
approved the entire experimental protocol. Nine-week-old
ICR mice were purchased from Japan Clea (Tokyo, Japan).
All animals were kept under local vivarium conditions
(temperature 23.3°C, humidity 55% and a 12-h on/off light
cycle).
Sixteen-week-treatment experiment
Fifty-nine, 9-week-old, female ICR mice were either ovariec-
tomized (n = 43) or sham-operated (n =8 ) .A f t e ram o n t h ,
during which all mice were fed with conventional rodent food
pellets, the ovariectomized mice were divided into six groups.
In addition to the OVX group (n = 8), five groups (n =7 )
received medication, which was switched at the 8-week
midpoint. In the K to R group, mice were treated with MK-4
for 8 weeks and then with risedronate for eight more weeks.
R to K mice were treated with risedronate first and then with
vitamin K2.Kt oW O ,Rt oW O ,a n dR / Kt oW Om i c e
received either vitamin K2, risedronate, or both for 8 weeks,
and then the drug(s) was withdrawn. Except in the OVX
groups during K and R/K period, which received pellets
containing 50μg/100 g vitamin K2 (MK-4), all animals
received the conventional rodent food. Both the conventional
rodent pellets (CE-2) and the vitamin K2 pellets were
prepared by Japan Clea with MK-4 kindly provided by Eizai
(Tokyo, Japan). Calculated from the average 6 to 7 g a day
consumption of the ration, the pellets were prepared so that
the animals received ~100μg MK-4/kg/day, which is at a
dietary level. During the R or R/K period, mice received
0.25 mg/kg of daily oral risedronate after 2-h fasting. They
were fed after another 2-h fasting. The femurs were excised
from mice euthanized after the 16-week therapeutic period
and were preserved at −80°C for microfocused X-ray
computed tomography (micro-CT) and peripheral quantitative
computed tomography (pQCT) analyses and confocal Raman
spectroscopy.
Eight-week-midpoint experiment
To examine femurs at the 8-week midpoint, total of 42 ICR
mice were treated under similar conditions to those of the
16-week experimental animals. They underwent either sham
surgery (n =9 )o ra no v a r i e c t o m y( n = 33). OVX groups
include control OVX (OVX, n = 9), OVX treated with
risedronate (OVX-R, n =8 )o rv i t a m i nK 2 (OVX-K, n =8 ) ,
and the concomitant administration (OVX-R/K, n =8 ) .
Microfocused X-ray computed tomography
Using MCT-CB 130F (Hitachi Medico, Tokyo, Japan),
three-dimensional imaging data of the distal epiphyseal
region of the femur, between 1.5 to 2.75 mm proximal to
the growth plate, were obtained. The spatial resolution was
set to 7µm with the voxel size of 17.8 × 17.8 × 17.8 (µm),
and the tube voltage and current were 60 kV and 100µA,
respectively. The resolution was set to medium (200
projections each), and slice thickness and increment were
set to 20µm. A morphological analysis was carried out
using TRI 3D BONE (Ratoc System Engineering, Tokyo)
for such parameters as BV (mm
3), bone volume; BS (mm
2),
bone surface; BV/TV (%), bone volume fraction; Tb.Th
(μm), trabecular thickness; Tb.N (1/mm), trabecular num-
ber; Tb.Sp (μm), trabecular separation; Tb.Spac (μm),
trabecular Space; FD, fractal dimension [19]; and structural
model index, SMI [20].
Peripheral quantitative computed tomography
The distal metaphysis, 1.4 mm proximal to the growth plate
and mid-diaphysis of femurs (5 mm proximal to the
midpoint), was scanned by a Research SA+ pQCT model
(Norland Stratec, Berkenfeld, Germany) with a tube voltage
of 50 kVand a tube current of 550µA using a voxel size of
1864 Osteoporos Int (2009) 20:1863–187280 × 80 × 46 (µm). The cortical bone was defined as the area
of bone mineral density (BMD)>690 mg/mm
3,w h i l ea
threshold of 395 mg/mm
3 at the contour mode 1 was set to
define trabecular bone in the bone marrow. Total BMD (mg/
cm
3) and the content, BMC (mg/mm), were presented as
metaphyseal mineral properties. In addition, the cortical
thickness (CTh), cross-sectional moment of inertia (CSMI),
and polar stress/strain index (pSSI), an index of strength
[21], were calculated.
Mechanical properties of femurs
Thebonestrengthofthefemoraldiaphysisanddistalepiphysis
was evaluated using three-point breaking tests and compres-
sion tests using a MZ-500 s device (Maruto, Tokyo, Japan).
The crosshead speed in the three-point breaking test and the
compression test was 10 and 1.0 mm/min, respectively. In the
latter, the distal epiphysis, approximately 3.0 mm thick, was
compressedto1.5mm.Theultimateload(UL)andstiffness(s)
were determined from the load–displacement curve and were
converted to the material properties. Ultimate stress (US) was
calculated by using the equation US = (UL×d×L)/(8×
CSMI), where d is the diameter at midshaft, and L is the
support span at the bottom (10 mm). The elastic modulus, E,
was calculated by using the equation E=(s×L
3)/(48×CSMI).
Confocal Raman spectroscopic measurements
Confocal laser Raman microspectroscopy was used to
examine the composition and relative amounts of the
mineral and matrix produced in the tibia. Raman spectros-
copy is particularly useful for bone analysis because it
probes the molecular and ionic vibrations of the mineral
and matrix component in unprocessed preparations that
preserve these components. The innate, prominent vibra-
tions were measured as described by Tarnowski et al. [22].
Crystallinity was determined using the method reported by
Yerramshetty et al. [23] as the inverse of the width of the
phosphate symmetric stretch band (PO4
3−ν1 at 959 cm
−1)a t
half the maximum intensity value. A Nicolet Al.mega XR
Dispersive Raman microscope system equipped with the
OMNIC Atlμs™ imaging software program (Thermo
Fisher Scientific, MA, USA), which enable to map a small
area less than 1μm
3 on the bony microsurface of the
cortical bone on the video microscope stage control. A high
brightness, low-intensity laser operating at 780 nm was
used as the excitation source with a laser power of 35 mW.
Each spectrum is the sum of ten 10-s measurements. The
spectral resolution of the Almega XR under the conditions
used was 3.85 cm
−1. For each femur, one averaged Raman
image was acquired in the middle of the anterior cortical
bone by the ten 10-s measurements.
Statistical analysis
All data values were expressed as the means±standard
deviation(SD).Unlessotherwisementioned,thegroupmeans
for each parameter were determined for the 8-week midpoint
experimental results and compared using a one-way analysis
of variance (ANOVA), with the post hoc Tukey–Kramer test.
Fig. 1 Materialpropertiesofthefemoralmid-diaphysis(top panels)a n d
of the femoral distal epiphysis (bottom panels). After the 16-week
treatments with risedronate and/or MK-4, the three-point bending test
and compression test were carried out as described in the “Materials and
methods” section for the diaphyseal and epiphyseal mechanical strength
analyses, respectively. Open and filled bars represent the sham and
OVX controls, respectively. The bars of graded shading represent the
treatment groups. The data are expressed as the means±SD and
compared using an ANOVA and post hoc Dunnett's multiple
comparison test vs. OVX controls. *p < 0.05 was considered significant
Osteoporos Int (2009) 20:1863–1872 1865Dunnett's multiple comparisons test was used for 16-week
treatment groups with the OVX group as a reference. The
probability values of p < 0.05 were considered to be
statistically significant for all the comparisons. The Stat
View software package (Stat View 5.0; Abacus Concepts,
Berkeley, CA, USA) was used for all analyses.
Results
Body weight and length of femur
The body weight, which was 33.6 ± 2.1 at the ovariectomy
(−4 weeks), ranged from 37.4 ± 2.1 to 40.3 ± 3.0 g at
0 week in the sham and OVX groups. At 8 and 16 weeks,
the range in all groups was between 40.9 ± 2.7 and
44.3 ± 4.3 g and 43.6 ± 7.5 and 49.4 ± 7.0 g, respectively.
The length of the femur at the time they were killed ranged
between 17.5 ± 0.6 and 17.8 ± 0.4 mm. Neither body
weight nor the length of femur showed any significant
difference in any of the treatment groups compared to the
OVX or sham group (data not shown). While the body
weight in OVX groups tended to be larger at 0 and 8 weeks,
no significant effect was detected (data not shown). No
intergroup difference was detected either (data not shown).
Mechanical tests of femurs after the 16-week treatments
As shown in the Fig. 1, the bending strength of the femoral
diaphysis (top panels) and the compressive strength of the
Fig. 2 Mineral and geometric properties at 8-week midpoint and 16-
week termination. a Bone mineral density (BMD) and content (BMC)
in femur diaphysis and metaphysis and (b) cortical thickness, CSMI,
and the polar SSI in femur diaphysis. The data are expressed as the
means±SD, and *p < 0.05 represents significance. ANOVA followed
by post hoc Tukey–Kramer paired multiple comparison test (at
8 weeks) or Dunnett's multiple comparison test vs. OVX controls (at
16 weeks) were used. At 16 weeks, significance (p < 0.05) of each
parameter determined by t test against the corresponding 8-week
midpoint value was marked by a. The bars are similarly marked to
those in Fig. 1
1866 Osteoporos Int (2009) 20:1863–1872femoral distal metaphysis (bottom panels) were tested. In
comparison to the OVX bone, a significant difference was
detected in the sham bone as revealed by the elastic
modulus as well as the ultimate stress values. The deficit
in the OVX was restored in K to R in all four parameters, R
to WO in the ultimate stress by three-point bending test,
and K to WO in the ultimate stress by compression test.
Changes in the cortical bone quality
Right panels in Fig. 2 show the results at the 16-week
termination. The OVX control group showed a significant
decrease in the cortical BMD and BMC as well as thinning
of the cortical thickness and a decreased pSSI in comparison
to the sham group. The final 16-week cortical BMD, BMC
(Fig. 2a) and thickness (Fig. 2b) did not significantly change
by any treatment from the 8-week stage except in the K to R
cortical BMC. Among the treated groups, only the K to R
group showed significantly higher values (lower in CSMI)
than the OVX controls in all the parameters presented.
Unless followed by risedronate, treatment by MK-4 did not
significantly increase mineral content or density neither in
diaphysis nor in metaphysis. Only in the K to R group was
CSMI significantly smaller than the 16-week OVX control.
The K to R femur alone also raised the pSSI value, the
calculated index of strength, to the levels of the sham group
during the later 8-week treatment by risedronate (Fig. 2b).
When we compare CSMI values in the 16-week treatment
groups to their respective 8-week values by the Student's
t test, many groups, including sham, OVX, R to K, R to WO,
and K to WO, significantly increased the values during the
later 8-week treatment. In the R/K to WO, CSMI retained
similar high values with similarly large SD to the OVX-R/K
8-weekmidpoint.TheRtoWOgroupbutnotR/KtoWOwas
also distinct showing significantly higher values than the
OVX control in both cortical BMC and thickness.
Analysis of Raman spectra (Fig. 3) revealed that the
resolvable mineral factor was of a carbonated apatite almost
identical to what was reported by Tarnowski et al. [22]
(PO4
3−ν1, 959 cm
−1;P O 4
3−ν4, 580 cm
−1;C O 3
2−ν1,
1,072 cm
−1), and the matrix factor was of a collagenous
protein (amide I, 1,666 cm
−1; amide III, 1,242 and
1,269 cm
−1;C H 2 wag, 1,450 cm
−1; hydroxyproline, 855
and 878 cm
−1; proline, 919 cm
−1; HPO4
2−, 1,005 cm
−1;
data not shown). While mineral properties such as the
crystallinity were unchanged in all groups throughout the
Fig. 2 (continued)
Osteoporos Int (2009) 20:1863–1872 186716-week experiment, the cortical mineral to matrix ratio
measured by PO4
3−ν1/amide I was significantly lower, and
Hypro/Pro ratio was significantly higher only in OVX-K at
8 weeks than the OVX controls. At 16 weeks, the PO4
3−ν1/
amide I ratio significantly increased in K to WO alone,
revealing the decreased collagenous matrix by the MK-4
withdrawal. Hypro/Pro ratio was all similar at 16 weeks.
Changes in the trabecular architecture
The effects of K to R on the distal metaphyseal (Fig. 2a)
and the distal epiphyseal trabeculi (Table 2 and Fig. 4) were
also quite significant. In Tables 1 and 2, the structural
parameters by micro-CT analysis are summarized. In
comparison to the OVX controls, sham group showed
significant differences in the BV, BS, BV/TV, Tb.Th, Tb.N,
and FD (larger) and Tb.Sp (smaller) at 8 weeks. All three 8-
week treatment groups, OVX-R, K, and R/K, showed
significant difference from the OVX group in many
parameters (Table 1). Of note, the concomitant administra-
tion, OVX-R/K, was no more effective than the OVX-K or
OVX-R monotherapy. The effect of 16-week treatment with
MK-4 and/or risedronate was as follows. Both K to R and K
to WO groups showed significantly better BV, BS, BV/TV,
Tb.N, and Tb.Sp values in comparison to the OVX group
(p < 0.01 in K to R). Figure 2a also shows that K to R and R
to K groups were higher in the metaphyseal total BMD and
BMC, while BMC values were also higher in the R to WO
and R/K to WO. Risedronate raised metaphyseal total BMC
by more than 50% in K to R during the later 8 weeks. On the
other hand, the R to WO and R/K to WO groups
significantly lowered Tb.Th in comparison to the OVX
control group (Table 2). In contrast to the MK-4 withdrawal,
R to WO and R/K to WO lowered other trabecular structural
parameters as well to the levels of OVX controls (Table 2).
Figure 4 represents reconstructed 3-D images at 16 weeks of
the distal epiphyseal region. The trabecular architecture
looked poor in the OVX control and R/K to WO groups.
Discussion
Generally, drugs targeting different functions are combined
for multidrug therapy with the expectation of complemen-
tary action. For vitamin K, however, even the efficacy by
itself is still controversial. Earlier, low concentrations of
8-week treatment 16-week treatment 
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Fig. 3 Analysis of femur diaph-
yseal cortex by confocal laser
Raman microspectroscopy.
PO4
3−ν1 at 959 cm
−1 was used
as a mineral parameter and the
amide I at 1,666 cm
−1, and
hydroxyproline (Hypro) at 855
and 878 cm
−1 and proline (Pro)
at 919 cm
−1 were used as matrix
parameters. The spectral band
intensity by peak area, height for
the Hypro/Pro ratio, or the band
width for crystallinity was col-
lected at each band as described
in the “Materials and methods”
section. The values are com-
pared among 8- and 16-week
samples, respectively, and
between 8- and 16-week
samples as in Fig. 2. Except for
the Hypro/Pro ratio, which was
based on the Fischer's LSD test,
statistical analysis used was the
same as in Fig. 2
1868 Osteoporos Int (2009) 20:1863–1872circulating vitamin K have been associated with bone
fractures [24] and with low bone mineral density [25]. The
undercarboxylated osteocalcin was associated with fracture
risk [26, 27], and its reduction by the vitamin K intake was
reported without the effect on BMD [28]. Furthermore, a
vitamin K intake level of less than 109μg/day has been
reported to be a risk factor for hip fracture in women [29].
Shiraki et al. treated postmenopausal patients with 45 mg/
day MK-4 and reduced the new fractures to one third. Their
lumber BMD was found to be significantly higher than that
observed in the control women [10]. In a more recent study,
the combination of alendronate with 45 mg/day MK-4 was
reported to be superior to alendronate monothrapy in
decreasing undercarboxylated osteocalcin, increasing fem-
oral neck BMD and decreasing the urinary deoxypyridino-
line [30]. In the animal studies, a much higher dosage of
30–50 mg MK-4/kg/day has been used, thus resulting in a
significantly higher mineral content in cortical bone without
bisphosphonate [31]. However, the results are inconsistent
among different animals or strains [16–18, 32–34]. In the
present study, we did not observe significant increase in
BMD or BMC at the lower level of ~100μg/kg/day unless
MK-4 was followed by risedronate.
Vitamin K2 has been known to be essential for the γ-
carboxylation of osteocalcin [35]. Therefore, the function
was once assumed through activating osteoblasts and
Table 1 Three-dimensional structural parameters of epiphyseal trabecular bone at 8 weeks
BV (mm
3) BS (mm
2) BV/TV(%) Tb.Th (μm) Tb.N (/mm) Tb.Sp (μm) FD SMI
Sham 0.69±0.15
a 24.7±5.3
a 30.5±5.8
b 54.7±3.2
b 5.5±0.9
b 137.3±75.1
a 2.3±0.0
b 2.7±0.2
OVX control 0.27±0.05 11.8±1.8 14.1±4.7 45.2±1.3 3.1±0.5 334.7±26.0 2.1±0.0 2.7±0.2
OVX-K 0.67±0.05
a 27.3±1.7
a 29.5±1.8
a 48.2±0.9 5.8±0.2
a 127.6±24.5
a 2.3±0.0
b 3.1±0.2
OVX-R 0.56±0.01
a 22.8±1.5
a 22.7±1.8 47.7±1.2 4.6±0.5 190.9±19.1
b 2.2±0.0 3.2±0.3
b,c
OVX-R/K 0.65±0.06
a 24.3±1.7
a 25.9±1.8
b 50.6±0.9 4.8±0.2 165.7±24.9
b 2.2±0.0 3.4±0.3
b,c
Data are expressed as means±SD. Group comparisons were performed by analysis of variance (ANOVA) followed by Tukey–Kramer test.
No significant difference was detected between OVX groups
ap < 0.01 vs OVX controls
bp < 0.05 vs OVX controls
cp < 0.05 vs sham
Fig. 4 Representative 3-D
images of the distal epiphysis
between 1.5 and 2.75 mm prox-
imal to the growth plate after the
16-week treatments. Micro-CT
images were reconstructed as
described in the “Materials and
methods” section
Osteoporos Int (2009) 20:1863–1872 1869leading them to enhanced mineralization [36]. The mice
genetically deficient for osteocalcin, however, exhibited the
gain in bone mass instead of loss [37], suggesting that the
osteoprotective action of vitamin K is mediated by some
other pathways. Recent reports showed that vitamin K2
activates osteoblastic transcription of extracellular matrix-
related genes [38] through steroid and xenobiotic receptor
(SXR)/pregnane X receptor (PXR)-mediated Msx2 gene
transcription in cooperation with the estrogen-bound ERα
[14].
According to the findings of our 8-week administration,
only the MK-4 monotherapy at the dietary level resulted in
cortical bone matrix formation and maturation without
significant increase in BMD or BMC. It was shown that
vitamin K2 not only stimulates cortical bone matrix
formation but also accelerates proline hydroxylation, which
is a prerequisite for collagen cross-linking to achieve a
mature collagenous matrix. Whether the enzymes involved
in these processes are the target of vitamin K2 or not is yet
to be resolved. In addition, MK-4 alone provided signifi-
cant effect in most of the structural parameters of femoral
trabecular bone. On the other hand, risedronate, at
0.25 mg//kg/day, was certainly effective, alone or in
combination with MK-4, in femoral cortical BMD, BMC,
and some trabecular structural parameters in the 8-week
treatment. Of note, however, the 8-week concomitant
administration was no more effective than each effective
monotherapy. This led us to investigate the sequential
administration of the two drugs with the same total dosage.
The resulting final mechanical properties at 16 weeks were
significantly better than the OVX controls only in K to R
group. Despite of beneficial effects of 8-week MK-4
pretreatment on the cortical bone matrix, enhanced degra-
dation of collagen seems to occur if the MK-4 is
discontinued. In other words, the elevated 16-week miner-
al/matrix ratio in K to WO is distinct from the lowest 8-
week midpoint ratio in the OVX-K. In contrast, the K to R
group retained a much lower mineral/matrix ratio at
16 weeks. Since the K to WO mineral value, the numerator,
is lower than the K to R value judged from the cortical
BMD, the higher mineral/matrix ratio in K to WO was
derived from the denominator, the smaller matrix value. It
suggests either the collagen degradation or the decreased
synthesis after the MK-4 withdrawal. An elevated serum
CTx value was observed in K to WO in the later 8 weeks
(data not shown). During the later 8-week treatment in K to
R, risedronate clearly prevented the increase in CSMI,
which occurred in K to WO. The lack of such prevention as
well as the lack of other beneficial effects found in K to R
cortex, such as the higher/larger BMD, BMC, and
thickness, would explain why no significant effect was
detectable in K to WO by the three-point bending test. In
the MK-4 treated pre-OVX rats, Iwamoto et al. reported the
elevated eroded surface as well as the bone formation rate
that remained high after the MK-4 withdrawal [16]. The
cellular mechanisms of the elevated collagen degradation
therefore have to be confirmed in the future.
In the compression test, the ultimate stress parameter of
K to WO as well as of K to R was significantly larger than
the OVX control. This result was supported by the
significantly better parameters of the trabecular structure
in K to WO such as BV, BS, BV/TV, Tb.N, and Tb.Sp in
comparison to the OVX controls. No such benefit was
observed in R to WO and R/K to WO. The difference in the
effect of MK-4 withdrawal on cortical bone and trabecular
bone may be related to the distinct distribution of ERα vs.
ERβ [39] or the different ERα signaling pathways [40], on
the assumption that vitamin K and estrogen via the ERα
cooperatively promote the osteoblast function through the
Msx2 gene induction [14].
Concomitant administration of risedronate and MK-4 is
probably not recommended because R/K to WO was
generally not beneficial except in the metaphyseal total
BMC. In addition, R to WO but not R/K to WO cortical
Table 2 Three-dimensional structural parameters of epiphyseal trabecular bone at 16 weeks
BV (mm
3) BS (mm
2) BV/TV (%) Tb.Th (μm) Tb.N (/mm) Tb.Sp (μm) FD SMI
Sham 0.14±0.05
b 8.0±3.2
b 6.3±2.0
b 35.4±2.0 1.8±0.6
b 602±273
b 1.9±0.0 2.6±0.2
Control 0.08±0.03 5.1±1.6 3.6±1.0 32.0±3.1 1.1±0.3 944±279 1.8±0.1 2.7±0.1
K to R 0.22±0.06
a 12.9±2.7
a 8.9±2.4
a 34.2±3.9 2.6±0.5
a 369±100
a 2.0±0.1 2.5±0.1
K to WO 0.15±0.06
b 9.8±3.8
b 6.7±2.6
b 31.0±3.8 2.1±0.8
b 536±291
b 1.9±0.1 2.5±0.1
R to K 0.14±0.03
b 7.8±1.9 6.0±1.4 33.6±3.5 1.7±0.4 733±376 1.9±0.1 2.6±0.1
R to WO 0.07±0.03 5.6±2.3 3.5±1.0 26.0±1.8
a 1.3±0.3 771±225 1.7±0.1 2.8±0.1
R/K to WO 0.10±0.04 6.8±2.7 3.9±1.7 27.7±2.3
b 1.4±0.6 828±397 1.8±0.1 2.8±0.1
Data are expressed as means±SD. Group comparisons were performed by analysis of variance (ANOVA) followed by Dunnett's test vs. OVX
controls
ap < 0.01
bp < 0.05
1870 Osteoporos Int (2009) 20:1863–1872thickness and BMC are significantly higher at 16 weeks
than the OVX control, resulting in the increased ultimate
stress only in R to WO. Since OVX-R and OVX-RK at
8 weeks exhibited similar cortical thickness and BMC
values, the negative effect of RK withdrawal is apparent.
The continuous 16-week administration of risedronate and
MK-4 (R/K to R/K) was not beneficial in any parameters
tested, including the metaphyseal total BMC (data not
shown). Although R to K also showed a significantly
positive effect in metaphyseal total BMD and BMC, it is
probably not recommended to follow R by K because none
of the benefits available in the cortex of R to WO was seen
in R to K. In conclusion, prior 8-week treatment with MK-4
followed by the 8-week risedronate prevented the short-
comings of individual drugs and significantly increased
femur strength of ICR mice compared to the OVX controls.
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